Contents

Contents

JOURNAL OF HEPATOLOGY VOLUME 54, ISSUE 3, PAGES 401–596 M. Nakagawa, M. Watanabe, M. Sakamoto, S. Maekawa, A. Sakai, S. Kaneko, K. Ito, N. Masaki, K. ...

246KB Sizes 4 Downloads 80 Views

JOURNAL OF HEPATOLOGY VOLUME 54, ISSUE 3, PAGES 401–596 M. Nakagawa, M. Watanabe, M. Sakamoto, S. Maekawa, A. Sakai, S. Kaneko, K. Ito, N. Masaki, K. Tokunaga, N. Izumi, M. Mizokami

EDITORIALS 401

The quest for equity in liver transplantation: Another lesson learned from women. F. Durand

403

Long distance calling for liver regeneration: Identification of neuroendocrine signalling pathways activated after partial hepatectomy. M.A. Avila

406

Regulation of the expression of the hepatocellular sulfate–oxalate exchanger SAT-1 (SLC26A1) by glyoxylate: A metabolic link between liver and kidney? B. Stieger

RESEARCH ARTICLES Viral Hepatitis 408

415

422

432

439

449

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J.G.P. Reijnders, V. Rijckborst, M.J. Sonneveld, S.M.J. Scherbeijn, C.A.B. Boucher, B.E. Hansen, H.L.A. Janssen

Cirrhosis 455

Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. D. CazalsHatem, S. Hillaire, M. Rudler, A. Plessier, V. Paradis, B. Condat, C. Francoz, M.-H. Denninger, F. Durand, P. Bedossa, D.C. Valla

Transplantation 462

Gender, renal function, and outcomes on the liver transplant waiting list: Assessment of revised MELD including estimated glomerular filtration rate. R.P. Myers, A.A.M. Shaheen, A.I. Aspinall, R.R. Quinn, K.W. Burak

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. T. Kawaoka, C.N. Hayes, W. Ohishi, H. Ochi, T. Maekawa, H. Abe, M. Tsuge, F. Mitsui, N. Hiraga, M. Imamura, S. Takahashi, M. Kubo, T. Tsunoda, Y. Nakamura, H. Kumada, K. Chayama

Liver Failure and Growth 471

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. C. Sarrazin, S. Susser, A. Doehring, C.M. Lange, T. Müller, C. Schlecker, E. Herrmann, J. Lötsch, T. Berg

The protective role of hydrogen-rich saline in experimental liver injury in mice. H. Sun, L. Chen, W. Zhou, L. Hu, L. Li, Q. Tu, Y. Chang, Q. Liu, X. Sun, M. Wu, H. Wang

481

Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. I. Doignon, B. Julien, V. Serrière-Lanneau, I. Garcin, G. Alonso, A. Nicou, F. Monnet, M. Gigou, L. Humbert, D. Rainteau, D. Azoulay, D. Castaing, M.-C. Gillon, D. Samuel, J.-C. Duclos-Vallée, T. Tordjmann

489

The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIVinfected patients: A case control study. L. Cotte, T. Bénet, C. Billioud, P. Miailhes, J.-Y. Scoazec, T. Ferry, C. Brochier, A. Boibieux, P. Vanhems, M. Chevallier, F. Zoulim

Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J.-I. Riezu-Boj, E. Larrea, R. Aldabe, L. Guembe, N. Casares, E. Galeano, I. Echeverria, P. Sarobe, I. Herrero, B. Sangro, J. Prieto, J.-J. Lasarte Pathogenesis of lipid metabolism disorder in hepatitis C: Polyunsaturated fatty acids counteract lipid alterations induced by the core protein. H. Miyoshi, K. Moriya, T. Tsutsumi, S. Shinzawa, H. Fujie, Y. Shintani, H. Fujinaga, K. Goto, T. Todoroki, T. Suzuki, T. Miyamura, Y. Matsuura, H. Yotsuyanagi, K. Koike Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. M. Kurosaki, Y. Tanaka, N. Nishida, N. Sakamoto, N. Enomoto, M. Honda, M. Sugiyama, K. Matsuura, F. Sugauchi, Y. Asahina,

Cancer 497

Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. Y.-W. Li, S.-J. Qiu, J. Fan, J. Zhou, Q. Gao, Y.-S. Xiao, Y.-F. Xu

506

Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of b-catenin. M.D. Thompson, M.J. Dar, S.P.S. Monga

therapies. M.B. Zeisel, I. Fofana, S. Fafi-Kremer, T.F. Baumert

Molecular and Cell Biology 513

521

Glyoxylate is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells. N. Schnedler, G. Burckhardt, B.C. Burckhardt TGF-b1 mediated activation of Rho kinase induces TGF-b2 and endothelin-1 expression in human hepatic stellate cells. H. Shimada, N.R. Staten, L.E. Rajagopalan

Genetic and Metabolic Diseases 529

538

545

553

559

Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. E. Mutel, A. Abdul-Wahed, N. Ramamonjisoa, A. Stefanutti, I. Houberdon, S. Cavassila, F. Pilleul, O. Beuf, A. Gautier-Stein, A. Penhoat, G. Mithieux, F. Rajas G80S-linked ferroportin disease: Classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective. C.J. McDonald, D.F. Wallace, L. Ostini, S.J. Bell, B. Demediuk, V.N. Subramaniam Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. J.C. Hannukainen, R. Borra, K. Linderborg, H. Kallio, J. Kiss, V. Lepomäki, K.K. Kalliokoski, U.M. Kujala, J. Kaprio, O.J. Heinonen, M. Komu, R. Parkkola, M. Ahotupa, T. Lehtimäki, R. Huupponen, P. Iozzo, P. Nuutila Management of hepatocellular adenoma during pregnancy. J.E. Noels, S.M. van Aalten, D.J. van der Windt, N.F.M. Kok, R.A. de Man, T. Terkivatan, J.N.M. IJzermans Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. S.Y. Park, W.Y. Tak, M.K. Jung, S.W. Jeon, C.M. Cho, Y.O. Kweon, K.C. Kim

SPECIAL SECTIONS International Hepatology 577

Combination of gemcitabine and cisplatin for biliary tract cancer: A platform to build on. N. Razumilava, G.J. Gores

579

Abnormal nitrosothiol metabolism in hepatocellular carcinoma. J. Martin, J.-F. Dufour

581

Platelet-derived chemokines: New targets to treat liver fibrosis. O. Morales-Ibanez, R. Bataller

Controversies in Hepatology 584

Rolls Royce for everybody? Diagnosing liver disease by mini-laparoscopy. A.W. Lohse

586

First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. T. Poynard

LETTERS TO THE EDITOR 588

Changes in the 24-h plasma cortisol rhythm in patients with cirrhosis. S. Montagnese, B. Middleton, A.R. Mani, D.J. Skene, M.Y. Morgan

590

Adrenal insufficiency: Diagnosis in patients with liver cirrhosis is difficult. A. Galbois, D. Thabut

591

Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. S. Beinhardt, S. Rasoul-Rockenschaub, T.M. Scherzer, P. Ferenci

592

Silibinin in hepatitis C related liver transplantation. T. Berg, M. Biermer, UP. Neumann

593

Anemia – The overlooked factor in bleeding related to liver disease. J. Thachil

594

Anemia as a potential contributor to bleeding in patients with liver disease – Neglected but not forgotten. T. Lisman, S.H. Caldwell, R.J. Porte

REVIEW 566

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral

Registration of Clinical Trials The Journal of Hepatology endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005. More detailed information regarding clinical trials and registration can be found in New Engl J Med 2004; 351:1250– 1251 and New Engl J Med 2005; 352:2437–2438.

Cover image: Liver cell. Coloured scanning electron micrograph (SEM) of a hepatocyte. Magnification: 4,850 at 6  7 cm size. 16,000 at 7  9.5". (Source: Keystone/Science Photo Library SPL)